An open-label, multicenter phase 1 study investiaging the combination of RAD001 [everolimus], cetuximab and irinotecan as second-line therapy after FOLFOX [fluorouracil, folinic acid, oxaliplatin] (or XELOX [capecitabine, oxaliplatin]) plus bevacizumab (if given as part of local standard practice) in patients with metastatic colorectal adenocarcinoma.

Trial Profile

An open-label, multicenter phase 1 study investiaging the combination of RAD001 [everolimus], cetuximab and irinotecan as second-line therapy after FOLFOX [fluorouracil, folinic acid, oxaliplatin] (or XELOX [capecitabine, oxaliplatin]) plus bevacizumab (if given as part of local standard practice) in patients with metastatic colorectal adenocarcinoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Cetuximab; Everolimus; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Acronyms TRACT
  • Sponsors Novartis
  • Most Recent Events

    • 03 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Company (Novartis Pharmaceuticals Corporation) added as trial sponsor as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Actual initiation date changed from Apr 2007 to May 2007 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top